Trials / Completed
CompletedNCT02044627
Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002
A Phase 1, Open-Label,Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002 in Healthy Male Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Esperion Therapeutics, Inc. · Industry
- Sex
- Male
- Age
- 30 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This Phase 1 study will assess the mass balance recover of carbon-14 (14C) labelled ETC-1002 and the routes and rates of excretion of \[14C\]-ETC-1002
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C-ETC-1002] |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2014-01-01
- Completion
- 2014-01-01
- First posted
- 2014-01-24
- Last updated
- 2019-02-15
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02044627. Inclusion in this directory is not an endorsement.